Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aarey Drugs & PharmaceuticalsBOM:524412 -0.30%62 PB Ratio is 1.56 as of Aug. 16, 2026, which is 61% above its 10-year median of 0.97. GuruFocus rates BOM:524412 with a GF Score™ of 62/100 and a GF Value™ of ₹58.32 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 923 Drug Manufacturers companies, Aarey Drugs & Pharmaceuticals ranks better than 59.91% on this metric.
The historical rank and industry rank for Aarey Drugs & Pharmaceuticals's PB Ratio or its related term are showing as below:
BOM:524412'
s PB Ratio Range Over the Past 10 Years
Min: 0.35 Med: 0.97 Max: 4.4
Current: 1.56
During the past 13 years, Aarey Drugs & Pharmaceuticals's highest PB Ratio was 4.40. The lowest was 0.35. And the median was 0.97.
BOM:524412's PB Ratio is ranked better than 59.91% of 923
companies
in the Drug Manufacturers industry
Industry Median: 1.97
vs BOM:524412: 1.56
During the past 12 months, Aarey Drugs & Pharmaceuticals's average Book Value Per Share Growth Rate was 9.00% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 4.70% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 4.10% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 8.00% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Aarey Drugs & Pharmaceuticals was 20.50% per year. The lowest was -17.50% per year. And the median was 6.50% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Aarey Drugs & Pharmaceuticals PB Ratio Related Terms
Aarey Drugs & Pharmaceuticals PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Aarey Drugs & Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aarey Drugs & Pharmaceuticals PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Aarey Drugs & Pharmaceuticals's PB Ratio distribution charts can be found below:
* The bar in red indicates where Aarey Drugs & Pharmaceuticals's PB Ratio falls into.
Aarey Drugs & Pharmaceuticals PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Aarey Drugs & Pharmaceuticals (BOM:524412) has a PB Ratio of 1.56 as of Aug. 16, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Aarey Drugs & Pharmaceuticals and its competitors. This is 61% above median its historical median of 0.97. Over the past decade, Aarey Drugs & Pharmaceuticals' PB Ratio has ranged from 0.35 to 4.40. According to the industry distribution chart, Aarey Drugs & Pharmaceuticals ranks #370 out of 923 companies in the Drug Manufacturers industry, placing it in the top 40.1%.
Is Aarey Drugs & Pharmaceuticals' PB Ratio too high?
Aarey Drugs & Pharmaceuticals' current PB Ratio of 1.56 is 61% above median its 10-year median of 0.97. Over the past 10 years, this metric has ranged from a low of 0.35 to a high of 4.40. The Drug Manufacturers industry median PB Ratio is 1.97. Aarey Drugs & Pharmaceuticals' value of 1.56 is 20.8% below this industry median. Based on the distribution chart, Aarey Drugs & Pharmaceuticals ranks #370 out of 923 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Aarey Drugs & Pharmaceuticals has a GF Score™ of 62/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aarey Drugs & Pharmaceuticals' PB Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Aarey Drugs & Pharmaceuticals ranks #370 out of 923 companies for PB Ratio. This puts Aarey Drugs & Pharmaceuticals in the upper half of its industry. The industry median PB Ratio is 1.97. Aarey Drugs & Pharmaceuticals' value of 1.56 is 20.8% below this benchmark. Historically, Aarey Drugs & Pharmaceuticals' own PB Ratio has ranged from 0.35 to 4.40 over the past decade. While the company's 10-year median is 0.97 vs. the industry median of 1.97, Aarey Drugs & Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.97, based on 923 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aarey Drugs & Pharmaceuticals's current PB Ratio of 1.56 is 20.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Aarey Drugs & Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aarey Drugs & Pharmaceuticals's current PB Ratio is 1.56, which is 61% above median its own 10-year median of 0.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aarey Drugs & Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Aarey Drugs & Pharmaceuticals (BOM:524412) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹58.32, compared to a current price of ₹82.58 — trading 41.6% above its estimated fair value. The current PB Ratio is 1.56, which is 61% above median its 10-year median of 0.97 and 20.8% below the Drug Manufacturers industry median of 1.97. Aarey Drugs & Pharmaceuticals' overall GF Score™ is 62/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Aarey Drugs & Pharmaceuticals (BOM:524412), the current PB Ratio is 1.56 as of Aug. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aarey Drugs & Pharmaceuticals (BOM:524412) Overvalued in 2026?
Based on GuruFocus' analysis, Aarey Drugs & Pharmaceuticals stock appears to be overvalued.
The current stock price of ₹82.58 is trading 41.6% above its estimated GF Value™ of ₹58.32.
GuruFocus considers Aarey Drugs & Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for BOM:524412:
PB Ratio: 1.56 (61% above median its 10-year median of 0.97)
GF Value™: ₹58.32 vs. price of ₹82.58 (41.6% above fair value)
Industry Position: 20.8% below the Drug Manufacturers median (#370 of 923)
No single metric tells the full story. See the BOM:524412 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aarey Drugs & Pharmaceuticals Ltd is engaged in bulk drug manufacturing and offers products for industrial applications. The company manufactures active pharmaceutical ingredients, intermediates, and specialty chemicals. It is also involved in the trading of industrial solvents and chemicals. The products offered by the company include N-Methyl urea, Dimethyl urea, Mefenamic acid, Metformin, Doxaphylline, and BMD among others. The company principally carries out its business operations in India.
62GF Score
Get the complete analysis for BOM:524412
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524412 has been successfully added to your 
